Nearly 4 Billion-Dollar Market for IVD Packaging

In vitro diagnostic tests require specialized boxes, bottles, bags and plates to protects crucial chemicals and insure a quality result each time a test is performed. Thus it's not surprising that growth in IVD drives growth in packaging. That’s the conclusion of The Freedonia Group’s new study, In Vitro Diagnostic Test Packaging. Take two trends for example. The increasing use of point-of-care tests and the development of high-quality molecular testing supplies.

Direct-to-Consumer Services Put Down Roots in U.S. Lab Testing Market

Still framed as an open proposition in healthcare, the direct-to-consumer (DTC) lab testing market has already captured robust demand from U.S. consumers. Sales of DTC testing services have rapidly grown outside the traditional paradigm of physician-facilitated clinical testing. Kalorama Information’s Direct-to-Consumer Laboratory Testing Market has served as an important reference in recent articles by the New York Times, Forbes, and Becker’s Hospital Review. Whereas media coverage has focused largely on the medical implications of lab results communicated without physician guidance, market growth has proceeded briskly for DTC lab services through their considerable market strengths.

Luminex Acquisition of Nanosphere Continues Trend of Investment in Decentralized Molecular Testing

This blog post reviews the recent history of acquisitions and investment in the area of decentralized molecular diagnostics. Kalorama Information’s The Market and Potential for Molecular Point of Care Diagnostics provides the current market, projected future sales and total available markets in 2020 for molecular POC diagnostics for flu, strep A, RSV, CT/NG, group B strep (GBS), HPV, HSV, vaginitis, HIV, TB, hepatitis, malaria and many other disease areas.

On May 16, Luminex Corporation announced a definitive agreement with Nanosphere, Inc. to acquire the latter for approximately $58 million. The acquisition will broaden Luminex’s addressable market in clinical molecular testing, adding platform capabilities and clients outside of the Luminex ARIES platform and xTAG panels.  The Nanosphere Verigene and Verigene Flex platforms cater to the hospital market for automated molecular testing platforms, and could lead to opportunities in other decentralized markets for molecular testing (outside of centralized clinical labs or reference labs). Luminex’s acquisition of Nanosphere continues a string of company and technology acquisitions that have shaped the early molecular POC diagnostics industry.

miRNA Tools Lead Development of Next-Generation Therapeutics and Diagnostics

Although microRNAs (miRNAs) represent only a small fraction of the total RNA mass in a given sample – estimated at about 0.01% – the short RNA molecules (16-35 nucleotides) are widely viewed as a rich analytical resource for biomarkers and drug targets. Through broad gene regulation activity, miRNAs influence a range of cell processes and consequently play roles in various diseases including cancer, neurodegenerative disorders, and cardiovascular and autoimmune diseases. With potential applications in disease-specific diagnostics and therapeutics, miRNAs have become a focal point in the life science research tools market (instruments, reagents, procedures) profiled by Kalorama Information in MicroRNA Tools and Services Market. Tool markets in the report include qRT-PCR, hybridization (arrays) and next-generation sequencing (NGS) as well as miRNA research-specific reagents such as miRNA mimics and inhibitors.

Medical Devices: Growth Through Acquisitions, US Sales and R&D

Even with slight growth in the market, prospects in medical devices are promising for many firms. More promising than, for example, in the pharmaceutical industry, challenged by patent expirations and regulatory activity. Innovators can still win.  This is the finding of Kalorama Information's yearly study of medical devices.


Subscribe to Kalorama Information Home RSS